The Bladder Cancer Advocacy Network organized the UC-GENOME study and is now offering more grant funding to support clinical trials in bladder cancer.
The firm is aiming to commercialize its OncoPrism assay in 2023 as a laboratory-developed test to identify head and neck cancer patients eligible for checkpoint inhibitors.
Grail released updated data on Galleri from the PATHFINDER study, while Exact reported retrospective analysis on the performance of its test.
Analysis of 7,500 patients showed one-third had potentially actionable mutations and 10 percent were misdiagnosed, prompting calls for greater NGS use in this setting.
Experts are working through challenges to make low-cost sequencing available at resource-limited hospitals around the world, starting with an institution in Pakistan.
In the study, presented at SABCS, researchers developed an 812-gene signature that could identify which patients with ductal carcinoma in situ need aggressive treatment.
They hope the website will be an unbiased source for genetic risk information, testing, and financial support services and spur cascade testing in families.
Based on results from a pilot study, Dutch lawmakers are advancing a proposal to make WGS a standard test for advanced cancer patients.
In a retrospective analysis, ALL patients tested with NGS were less likely to achieve MRD-negative status than when tested with flow cytometry.